PMV Pharmaceuticals(US:PMVP)2026-03-06 13:01Financial Performance - The net losses for the years ended December 31, 2025, 2024, and 2023 were $78.0 million, $58.7 million, and $69.0 million, respectively, with an accumulated deficit of $446.7 million as of December 31, 2025[462]. - Total operating expenses for 2025 were $86.2 million, slightly higher than $85.4 million in 2024, with a loss from operations of $86.2 million compared to $85.4 million in the previous year[476]. - The company expects to incur substantial additional losses in the future, with cash operating expenditures of $73.6 million in 2025, up from $51.3 million in 2024[487]. - Cash used in operating activities for the year ended December 31, 2025, was $73.6 million, primarily due to a net loss of $77.7 million[491]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $112.9 million, with an accumulated deficit of $446.5 million[482]. Expenses - Research and development expenses increased to $69.9 million in 2025 from $58.5 million in 2024, primarily due to a $13.1 million increase in development and personnel-related expenses[477]. - General and administrative expenses decreased to $16.3 million in 2025 from $26.9 million in 2024, reflecting a reduction in facility-related costs and consulting expenses[478]. - Interest income, net, was $6.4 million for the year ended December 31, 2025, down from $10.7 million in 2024, primarily due to reduced interest rates on cash investments[478]. Assets and Liabilities - As of December 31, 2025, total financial assets were $112.9 million, a decrease of $70.4 million from $183.3 million in 2024, driven by a reduction in marketable securities[481]. - Current assets decreased to $115.2 million in 2025 from $175.7 million in 2024, while current liabilities decreased to $11.4 million from $14.4 million[481]. Clinical Development and Regulatory Plans - The company plans to submit a New Drug Application for rezatapopt in the first quarter of 2027 for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation[462]. - The Phase 2 pivotal portion of the PYNNACLE clinical trial for rezatapopt is expected to serve as a pivotal study, with the first patient dosed in the first quarter of 2024[462]. - The company anticipates significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[463]. Future Outlook - The company anticipates that its cash, cash equivalents, and marketable securities will be sufficient to fund operations until the end of the second quarter of 2027[487]. - The company has not yet commercialized any product candidates and does not expect to generate revenue from product sales for several years[482]. - The company may consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization to fund operations[488]. Cash Flow Activities - Investing activities provided $70.2 million of cash during the year ended December 31, 2025, mainly from maturities of marketable securities totaling $158 million[493]. - Financing activities generated $0.5 million in cash during the year ended December 31, 2025, from the exercise of stock options and issuance of common stock[495]. - The company did not sell any shares of common stock under the at-the-market equity offering program during the year ending December 31, 2025, leaving approximately $113.8 million available for future issuances[483]. Lease Obligations - Future lease payments for the 311 Pennington Sublease totaled $0.6 million as of December 31, 2025, with $0.1 million due within the next 12 months[485].